Zacks Research Brokers Increase Earnings Estimates for HALO

Key Points

• Zacks Research raised Halozyme Therapeutics’ Q3 2026 EPS estimate to $2.06 from $1.95 and projects Q3 2027 EPS of $2.16. Full-year consensus EPS is $7.77.
• Halozyme recently beat quarterly expectations, reporting $2.28 EPS versus the $1.79 consensus and $481 million in revenue, up 47.7% year over year. Analysts maintain a generally positive view, with a “Moderate Buy” consensus rating and average price target of $91.20.
• Shares opened at $107.72, near their 52-week high of $109.66, while insiders have sold $3.08 million worth of stock over the past 90 days. Institutional investors continue to own a substantial 97.79% of the company.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Stock analysts at Zacks Research boosted their Q3 2026 earnings per share (EPS) estimates for Halozyme Therapeutics in a research note issued to investors on Thursday, August 27th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $2.06 for the quarter, up from their prior estimate of $1.95. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $7.77 per share. Zacks Research also issued estimates for Halozyme Therapeutics' Q3 2027 earnings at $2.16 EPS.

Other research analysts also recently issued research reports about the company. Weiss Ratings upgraded Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday. Citigroup reaffirmed a "market outperform" rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. UBS Group restated a "buy" rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Morgan Stanley reduced their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a research note on Tuesday, May 12th. Finally, Wall Street Zen upgraded Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $91.20.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $107.72 on Wednesday. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock has a fifty day simple moving average of $88.52 and a two-hundred day simple moving average of $75.13. Halozyme Therapeutics has a 1-year low of $61.22 and a 1-year high of $109.66. The firm has a market cap of $12.23 billion, a price-to-earnings ratio of 32.16, a price-to-earnings-growth ratio of 0.43 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company had revenue of $481.00 million for the quarter, compared to analysts' expectations of $402.28 million. During the same period in the previous year, the business posted $1.54 EPS. The business's revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the firm's stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the sale, the director owned 14,462 shares of the company's stock, valued at $1,084,650. This trade represents a 33.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director owned 40,418 shares of the company's stock, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 32,478 shares of company stock worth $3,076,604 in the last ninety days. 2.50% of the stock is currently owned by insiders.

Institutional Trading of Halozyme Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in HALO. Measured Wealth Private Client Group LLC grew its position in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 124 shares in the last quarter. Larson Financial Group LLC lifted its stake in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 343 shares during the last quarter. MidFirst Bank bought a new stake in Halozyme Therapeutics during the second quarter worth about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter worth about $28,000. Finally, Quantbot Technologies LP bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at about $30,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source